ClinicalTrials.gg
CompletedNCT02329860Updated Jan 22, 2024Results posted

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

A Phase 3 interventional study of Apatinib and Placebo in Carcinoma, Hepatocellular, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2014, registered Dec 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing apatinib in Carcinoma, Hepatocellular — 18 open to participants now, 22 under way, 7 of them phase 3. apatinib · Carcinoma, Hepatocellular.

Enrollment
3rd of 41
400 · median 52
Started
2014
the only one that year
Phase 3
5 of 41
2 open now
Registered
1st of 41
by date
Lead sponsor
4 of 41
Jiangsu HengRui Medicine Co., Ltd.

Among the 41 studies testing apatinib in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

18 of the 41 studies testing apatinib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing apatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy).

Approximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to Apatinib or placebo (1/3 chance to receive placebo).

Primary endpoint of the study is overall survival.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old.
  2. Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of HCC (hepatocellular carcinoma) who cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation,and with at least one uni-dimensional by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to 1.1.
  3. Failure or intolerance to prior treatment with chemotherapy and/or targeted therapy (Failure is defined as documented radiological progression according to the radiology charter. Intolerance is defined as ≥ grade 4 hematologic toxicities, ≥ grade 3 non-hematologic toxicities ≥ grade 2 heart, liver or kidney damage).
  4. Systemic therapy must have been completed ≥2 weeks before randomization (AEs due to prior treatment ≤ grade 1).
  5. Liver function status Class A or B (score≤7).
  6. Barcelona Clinic Liver Cancer stage Category B or C.
  7. Performance Status of 0 or 1 within 1 week before randomization.
  8. of at least 12 weeks.
  9. ≤ 2000IU/ml or 1×10E+4 copy/ml.
  10. Adequate bone marrow, liver and renal function as assessed by the following laboratory tests conducted within 1 week before randomization.

    HB ≥ 90g/L; ≥1.5×10E+9/L; ≥80×10E+9/L; ALB ≥ 29g/L; and AST \< 5×; ≤1.5×ULN; Cr ≤1.5×ULN

  11. Women of and men must agree to use adequate .

Exclusion criteria

Exclusion Criteria:

  1. Any local treatment (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks of randomization.
  2. Known hepatic duct carcinoma, mixed cell carcinoma or fibrolamellar hepatocellular carcinoma, known history or suffering from other cancer(except of cured skin basal cell carcinoma or carcinoma in situ of cervix).
  3. Patients who will receive liver transplantation.
  4. Ascites with clinical symptoms, i.e. require Abdominal paracentesis or drainage treatment such as or Score>2.
  5. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg).
  6. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including male ≥ 450 ms, female≥ 470 ms).
  7. Grade III-IV cardiac insufficiency, according to criteria or echocardiography check: \<50%.
  8. Factors to affect oral administration(such as Patients unable to swallow oral medications, chronic diarrhea and ileus etc. situations evidently affect drug oral medication and absorption).
  9. Previous digestive tract bleeding history within 6 months or evident gastrointestinal bleeding tendency, such as,:Esophageal varices with bleeding risk, local active ulcerative lesions, fecal occult blood≥(++);if fecal occult blood(+),gastroscope check is required.
  10. The Within 28 days ahead of randomization, experience abdomen fistula, gastrointestinal perforation, or abdominal abscess
  11. Coagulation abnormalities ( > 1.5 x , or PT > ULN +4 seconds), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy;
  12. Occurrence of central nervous system or known brain metastatic;
  13. Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function damaged seriously etc.
  14. Proteinuria ≥ (++) or 24 hours total urine protein > 1.0 g.
  15. Received powerful inhibitor of within 7 days or powerful inducer of CYP3A4 within 12 days before randomization.
  16. Pregnant or breast-feeding women; patients with fertility will not or there is no way to adopt effective measures.
  17. Mental disorders history, or Psychotropic drug abuse history.
  18. Patients who has bone metastasis, has received Palliative radiotherapy (radiotherapy area > 5% marrow area).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Apatinib

    750 mg orally (p.o.) every day (qd), 28 days as one cycle

    Drug: Apatinib

  • Placebo comparator
    Placebo

    orally (p.o.) every day (qd), 28 days as one cycle

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: Approximately 36 months

Secondary outcomes

  1. Time to Progression(TTP)

    Time frame: Approximately 36 months

  2. Progression Free Survival (PFS)

    Time frame: Approximately 36 months

  3. Objective Response Rate

    Time frame: Approximately 36 months

  4. Disease Control Rate

    Time frame: Approximately 36 months

07

Results

Posted Jan 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneApatinibPlacebo
Started267133
Treated261132
Completed161107
Not completed10626

Outcome measures

PrimaryOverall Survival
Time frame:
Approximately 36 months
Reported as:
Median · months
Overall Survival
monthsApatinibPlacebo
Overall Survival8.7 (7.5 to 9.8)6.8 (5.7 to 9.1)
SecondaryTime to Progression(TTP)
Time frame:
Approximately 36 months
Reported as:
Median · months
Time to Progression(TTP)
monthsApatinibPlacebo
Time to Progression(TTP)4.7 (4.5 to 4.8)1.9 (1.9 to 2.0)
SecondaryProgression Free Survival (PFS)
Time frame:
Approximately 36 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsApatinibPlacebo
Progression Free Survival (PFS)4.5 (3.9 to 4.7)1.9 (1.9 to 2.0)
SecondaryObjective Response Rate
Time frame:
Approximately 36 months
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsApatinibPlacebo
Objective Response Rate10.7 (7.2 to 15.1)1.5 (0.2 to 5.4)
SecondaryDisease Control Rate
Time frame:
Approximately 36 months
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsApatinibPlacebo
Disease Control Rate61.3 (55.1 to 67.2)28.8 (21.2 to 37.3)

Adverse events

Collected over approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apatinib24/257 (9.3%)95/257 (37%)251/257 (97.7%)
Placebo13/130 (10%)30/130 (23.1%)110/130 (84.6%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventApatinibPlacebo
DeathGeneral disorders8/2579/130
Upper gastrointestinal haemorrhageGastrointestinal disorders13/2571/130
Lung infectionInfections and infestations8/2571/130
Hepatic encephalopathyNervous system disorders7/2571/130
OverdoseInjury, poisoning and procedural complications7/2572/130
Gastrointestinal haemorrhageGastrointestinal disorders5/2570/130
Hepatic function abnormalHepatobiliary disorders4/2571/130
HaemoptysisRespiratory, thoracic and mediastinal disorders4/2571/130
HaematuriaRenal and urinary disorders4/2570/130
PyrexiaGeneral disorders2/2572/130
Most frequent other events
Showing 10 of 56
Most frequent other events
EventApatinibPlacebo
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders144/2575/130
Platelet count decreasedInvestigations143/25723/130
Aspartate aminotransferase increasedInvestigations136/25743/130
Blood bilirubin increasedInvestigations133/25740/130
HypertensionVascular disorders123/25718/130
ProteinuriaRenal and urinary disorders114/25726/130
DiarrhoeaGastrointestinal disorders105/25721/130
White blood cell count decreasedInvestigations105/25710/130
Neutrophil count decreasedInvestigations97/25710/130
Alanine aminotransferase increasedInvestigations88/25728/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)ApatinibPlaceboTotal
Mean50.8 ± 10.750.3 ± 10.950.7 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)ApatinibPlaceboTotal
Female381654
Male223116339
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ApatinibPlaceboTotal
American Indian or Alaska Native000
Asian261132393
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ApatinibPlaceboTotal
China261132393
08

Study locations

1 site
  • Jiangsu hengrui medicine CO. LTD
    Lianyungang, Jiangsu 222047, China
09

References and documents

Publications

  • Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6. Epub 2021 May 8. PubMed 33971141 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Dec 2017, 44 months.

Results were first posted in Jan 2024, 6 years 1 month after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 44 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2014
First posted
Jan 1, 2015
StartActual
Mar 26, 2014
Primary completionActual
Dec 15, 2017
CompletionActual
Aug 14, 2019
Results first posted
Jan 22, 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02329860
Collaborators
NanJing PLA 81 Hospital
Responsible party
Sponsor
First posted
Jan 1, 2015
Start date
Mar 26, 2014
Primary completion
Dec 15, 2017
Completion
Aug 14, 2019
Results posted
Jan 22, 2024
Last update
Jan 22, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion